MUNIX: a sophisticated approach for motor unit number estimation
Event Details
Course introduction: In this eSeminar we will discuss MUNIX, a novel motor unit number estimation technique which has gained a lot of attention over the past decade especially as a
Event Details
Course introduction:
In this eSeminar we will discuss MUNIX, a novel motor unit number estimation technique which has gained a lot of attention over the past decade especially as a biomarker and outcome measure for ALS clinical trials. Emphasis will be put on how a standardized approach will result in high quality recordings suitable to track motor unit loss over time. In addition, the pitfalls, advantages, and disadvantages of MUNIX compared to other quantitative MUNE techniques will be discussed.
Learning Objectives:
At the conclusion of this seminar the participants will be able to:
- Be able to apply the method in their EMG lab.
- Recognize the scientific and clinical utility of MUNIX.
- Know about the most common pitfalls.
- Know about possible indications and limitations of the method.
This course is approved for 1.0 Hr. of Continuing Education by AAET – The American Association of Electrodiagnostic Technologists.
Speakers for this event
-
Dr. Markus Weber
Dr. Markus Weber
Dr. Markus Weber is head of the Neuromuscular Center/ALS Clinic in Switzerland and Professor of Neurology at the University of Basel, Switzerland. He graduated from the University of Bonn and received his training at various academic centres in Europe including the University of London, Institute of Neurology, Queens Square. After his training he spent three years as a neuromuscular research fellow at the Neuromuscular Diseases Unit, University of British Columbia, Vancouver Canada.
His research interests cover biomarker development, outcome measures, clinical neurophysiology, trial designs and cannabinoid research. His team has trained over 60 centers worldwide in a novel quantitative motor unit number estimation technique, MUNIX for clinical trials. In collaboration with the Department of Radiopharmaceutical Sciences, ETH Zurich and other European partners he is engaged in the development of a cannabinoid type 2 receptor PET ligand for brain and spinal cord imaging in ALS.
Markus Weber is a member of the ENCALS executive committee and serves on the advisory boards of several pharmaceutical and biotech companies
Time
(Tuesday) 11:00 am - 12:00 pm CST
Location
ONLINE eSeminar
